Latest Information Update: 29 Jun 1999
At a glance
- Originator XOMA
- Class Antifungals
- Mechanism of Action Cell membrane permeability enhancers
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Mycoses
Most Recent Events
- 29 Jun 1999 Discontinued-Preclinical for Mycoses in USA (Unknown route)
- 11 May 1999 No-Development-Reported for Mycoses in USA (Unknown route)
- 03 Sep 1996 New profile